Lys230
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Sumoylation Site Page: > Lys230  -  ELK1 (human)

Site Information
PPEAPNLkSEELNVE   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 3982502

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 2 ) , mutation of modification site ( 2 , 3 ) , western blotting ( 2 , 3 )
Disease tissue studied:
adrenal cancer ( 3 ) , pheochromocytoma ( 3 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 2 ) , Balb/c(10)1 (fibroblast) ( 3 ) , HeLa (cervical) ( 2 , 3 ) , PC-12 (chromaffin) ( 3 )

Downstream Regulation
Effects of modification on ELK1:
intracellular localization ( 3 )
Effects of modification on biological processes:
cell differentiation, inhibited ( 3 ) , transcription, inhibited ( 2 )

References 

1

Lumpkin RJ, et al. (2017) Site-specific identification and quantitation of endogenous SUMO modifications under native conditions. Nat Commun 8, 1171
29079793   Curated Info

2

Yang SH, Galanis A, Witty J, Sharrocks AD (2006) An extended consensus motif enhances the specificity of substrate modification by SUMO. EMBO J 25, 5083-93
17036045   Curated Info

3

Salinas S, et al. (2004) SUMOylation regulates nucleo-cytoplasmic shuttling of Elk-1. J Cell Biol 165, 767-73
15210726   Curated Info

4

Yang SH, Sharrocks AD (2004) SUMO promotes HDAC-mediated transcriptional repression. Mol Cell 13, 611-7
14992729   Curated Info

5

Yang SH, Jaffray E, Hay RT, Sharrocks AD (2003) Dynamic interplay of the SUMO and ERK pathways in regulating Elk-1 transcriptional activity. Mol Cell 12, 63-74
12887893   Curated Info